ICE Biopharma is a Swiss-based strategic consultancy advising biotechs on ex-US commercial strategy and execution. Our operational experience means we can advise and help execute key “No Regret Moves” that our clients must progress to preserve enterprise value, while keeping strategic options open.
Products, services, technology
For biotechs with innovative assets in Phase II or later who need to evaluate, define, and execute their optimal international strategy, keeping their strategic options open without compromising their US focus, ICE Biopharma is the Alpine Guide that demystifies international commercialization.
Cooperation possibilities
ICE Biopharma: partner of choice for innovative Biotechs evaluating international Commercialization. With multiple launch experience, we advise on go-to-market strategy and execution, enabling partners to fulfil their mission to patients, build enterprise value and preserve strategic optionality.
- https://icebiopharma.com/
- +41 79 592 23 17
- Send an email
- Francis Marsland
Some insights
By enabling successful launches, we ensure that European and Canadian patients have access to the innovative therapeutics they deserve.
Unlike large consultancies or companies incentivized to sell you their own contract sales forces, our guidance is 100% unbiased and grounded in lived operational reality. We walk alongside your leadership team to determine if, where, when, and how to bring your asset to international markets.
Biotechs advancing innovative assets must make US launch a success. Significant enterprise value impact sits in international markets.Tariffs, MFN, pricing pressures, regulatory & access hurdles make geographic expansion hard. We demystify the terrain and design the roadmap to international success.
We advise biotechnology companies on international commercialisation of innovative therapeutics.
The Swiss biotech ecosystem is a rich source of key talents and an emerging center for later-stage therapeutic development. It is also a great forum for business development and collaboration.
Biotech executives with late-stage or in-market therapeutics assets who want to evaluate their commercialization options internationally.